DNX-2401: an investigational drug for the treatment of recurrent glioblastoma

Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma

(2019) Brandon D. Philbrick et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma

(2018) Frederick F. Lang et al.   JOURNAL OF CLINICAL ONCOLOGY

OUP accepted manuscript

(2018)   NEUROSURGERY

Spatial and temporal proteome dynamics of glioma cells during oncolytic adenovirus Delta-24-RGD infection

(2018) Andrea González-Morales et al.   Oncotarget

Oncolytic adenovirus Delta-24-RGD induces a widespread glioma proteotype remodeling during autophagy

(2018) Andrea González-Morales et al.   Journal of Proteomics

Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?

(2018) E Antonio Chiocca et al.   NEURO-ONCOLOGY

Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?

(2018) Aleksei Stepanenko et al.   Cancers

Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival

(2016) Ranjith Babu et al.   JOURNAL OF NEUROSURGERY

Molecularly Targeted Drugs Plus Radiotherapy and Temozolomide Treatment for Newly Diagnosed Glioblastoma: A Meta-Analysis and Systematic Review

(2016) Jiahao Su et al.   ONCOLOGY RESEARCH

Novel chemotherapeutics and other therapies for treating high-grade glioma

(2015) Jennifer H Kang et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival

(2015) Marcos A. dos Santos et al.   JOURNAL OF NEURO-ONCOLOGY

Oncolytic viruses: a new class of immunotherapy drugs

(2015) Howard L. Kaufman et al.   NATURE REVIEWS DRUG DISCOVERY

C-Jun N-terminal kinases are required for oncolytic adenovirus-mediated autophagy

(2015) S R Klein et al.   ONCOGENE

Adenovirus’s last trick: You say lysis, we say autophagy

(2014) Hong Jiang et al.   Autophagy

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Delta-24-RGD Oncolytic Adenovirus Elicits Anti-Glioma Immunity in an Immunocompetent Mouse Model

(2014) Hong Jiang et al.   PLoS One

Update on Anti-angiogenic Treatment for Malignant Gliomas

(2014) John F. de Groot et al.   Current Oncology Reports

The treatment of glioblastomas: A systematic update on clinical Phase III trials

(2013) An-an Yin et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Standards of care for treatment of recurrent glioblastoma—are we there yet?

(2012) Michael Weller et al.   NEURO-ONCOLOGY

Human Adenovirus Type 5 Induces Cell Lysis through Autophagy and Autophagy-Triggered Caspase Activity

(2011) H. Jiang et al.   JOURNAL OF VIROLOGY

Oncolytic Adenovirus: Preclinical and Clinical Studies in Patients with Human Malignant Gliomas

(2009) Hong Jiang et al.   CURRENT GENE THERAPY

Glioblastoma multiforme: a review of where we have been and where we are going

(2009) Cory Adamson et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Delta-24-RGD in Combination With RAD001 Induces Enhanced Anti-glioma Effect via Autophagic Cell Death

(2008) Marta M Alonso et al.   MOLECULAR THERAPY